CINV Prophylaxis — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Use an NK1-receptor antagonist plus a 5-HT3 antagonist and dexamethasone, with olanzapine considered as part of the high-emetic-risk regimen
The best answer is “Use an NK1-receptor antagonist plus a 5-HT3 antagonist and dexamethasone, with olanzapine considered as part of the high-emetic-risk regimen”. Cisplatin has high emetogenic risk and inadequate control in the first cycle predicts further difficulty. Australian eviQ guidance uses multi-pathway prophylaxis: an NK1 antagonist, a 5-HT3 antagonist and dexamethasone, with olanzapine supported for high-risk regimens when sedation and other patient factors permit. Single-class strategies leave important acute or delayed pathways untreated; rescue-only treatment is inferior to prevention.
Reference: eviQ: Prevention of anti-cancer therapy induced nausea and vomiting: https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/gastrointestinal/7-prevention-of-anti-cancer-therapy-induced-nausea